Abstract

5523Background: In GOG 213, a phase III randomized trial designed to determine the impact of secondary cytoreduction and/or incorporation of anti-angiogenesis therapy on overall survival (OS) in re...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call